Corcept Therapeutics Faces Class Action Amid FDA Concerns

A securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and several of its executives, alleging that the company misled investors regarding the regulatory status of its lead product candidate, relacorilant. The suit, titled Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, claims that Corcept ignored multiple warnings from the U.S. Food and Drug Administration (FDA) prior to submitting its New Drug Application (NDA). The lawsuit seeks to recover losses incurred by investors who acquired CORT common stock between October 31, 2024, and December 30, 2025.

The law firm Hagens Berman, which specializes in shareholder rights, has urged affected investors to come forward to discuss their legal rights. According to the complaint, Corcept had portrayed relacorilant as being on the verge of approval, citing “powerful evidence” to support its claims. However, the lawsuit alleges that the FDA had cautioned the company on several occasions about the inadequacy of its clinical data.

The complaint indicates a concerning disconnect between Corcept’s public assertions and private communications from the FDA. Reed Kathrein, a partner at Hagens Berman leading the investigation, stated, “The litigation targets the alleged gap between Corcept’s ‘high confidence’ narrative and the private warnings from the FDA. Management reportedly knew of significant review issues yet continued to assure investors that no obstacles existed.”

Allegations of Misleading Information

The lawsuit outlines several key allegations against Corcept and its executives, claiming violations of the Securities Exchange Act of 1934. One significant point raised is the FDA’s explicit warning during pre-submission meetings regarding the sufficiency of the clinical development program assessing relacorilant’s impact on hypertension.

Evidence cited in the complaint suggests that the FDA indicated the likelihood of a rejection if Corcept proceeded with the NDA without additional data demonstrating effectiveness. This crucial information was reportedly not disclosed to shareholders, leading to substantial investor losses when the truth emerged.

On December 31, 2025, Corcept announced it had received a Complete Response Letter (CRL) from the FDA, causing its stock price to plummet from $70.20 to $34.80 in a single day. This sharp decline erased over $3.6 billion in market value, leaving investors grappling with the fallout.

The situation intensified when a redacted version of the CRL was released on January 30, 2026, confirming the FDA’s inability to conduct a “favorable benefit-risk assessment” without further data on the drug’s efficacy.

Next Steps for Investors

Investors who purchased Corcept shares during the class period have until April 21, 2026, to apply to the court to be appointed as Lead Plaintiff in the case. Those with significant losses or relevant information that may assist the investigation are encouraged to reach out to Hagens Berman.

Reed Kathrein can be contacted at 844-916-0895 or via email at [email protected]. The law firm emphasizes the importance of this upcoming deadline for investors seeking to assert their rights in court.

Whistleblowers with non-public information related to Corcept are also encouraged to consider reporting their findings, potentially benefiting from the SEC Whistleblower Program. This program offers financial rewards of up to 30 percent of any successful recovery made by the SEC.

Hagens Berman is recognized as a global leader in complex litigation focused on corporate accountability, representing not just investors but also workers, consumers, and whistleblowers. The firm has achieved notable successes, securing over $2.9 billion in settlements for those affected by corporate misconduct. More information about the firm can be found at hbsslaw.com.